ADN (ASX) General comments/chat

Originally posted by redapplecarts ↑

You asked how are the shorters attempting to manipulate the SP? Well let's look at their recent posts:
1. Hingdog compared ADN current SP to AVZ in 2018. The two companies are incomparable, having vastly different capex, jurisdiction, resource, management style, etc.
2. The percentage of market cap shorted is irrelevant. It's the percentage of shorts to daily volume that affects the share price.
3. You know nothing about our investment strategies yet deliver a condescending lecture on risk. Why is this manipulative? Because it casts us as fools without evidence. I am no fool. Over the past 18 months I've invested in 24 companies and currently hold shares in 11. I sold 13 for a total return of 27% because they hit my price target, or the company’s circumstances changed. I have a fixed initial capital investment that I won't exceed, precisely to manage risk. I am also overweight in ADN at 17% of my current holdings. So no topping up for me regardless of price. Others will have different investing rules. So far I’ve achieved a 155% return on capital over 18 months. I work fulltime, and therefore I don’t trade, I invest. Nick brags about making $3M over 3 years. But considering that includes salary, leave, super and tax, that's hardly spectacular. Certainly, its insufficient grounds to mock others' incomes.
4. No company benefits from a tanking share price, regardless of their capital needs. Traders don’t care about the company’s interests. Investors do.
5. Shorters love to call us baggies. This is manipulative. Why? Because it casts us as idiots again without evidence. Manipulators are typically narcissists. And narcissists , like toddlers, cannot imagine a world outside their own actions. Just because my investment strategies differ to yours does not make me an idiot. See point 3.
6. Nick claimed an ADN baggie tried to hack his account. Even if this really happened, how does he know its an ADN investor? What does the alleged hacker’s actions have to do with ADN? I suspect the purpose was to create drama to draw more attention to what I believe is an active short and distort campaign. Kaolin is a heterogeneous product, and HK has different and more valuable uses. The shorters derided it as “clay”. This is like calling diamonds squashed carbon, then saying a diamond mine is unviable given the spot price for carbon. This deliberate misinformation campaign is working, because of limited market understanding of HK.
7. Yes, ADN's market cap exceeded their old PFS’s NPV. Anyone that could count saw this. I believe ADN's prospects far exceed the old PFS. Here I refer to HPA and HK. You can call me a baggie. But I believe if humanity never invested in vision we’d still be stuck in the Stone Age. Many companies with yet unproven commercial technologies command large market caps. Investors support and value them on their future prospects.
And herein resides shorting’s despicable nature. Going long means investing in a future vision. Going short means investing in a dystopian one where innovation fails and progress stalls. Destroying value is easy. Creating it is hard. Worse still, shorters mock those trying to build a better world.
The biggest innovations carry the biggest risk. Either support the innovators or stand by the sidelines. But don't try and white ant progress for personal profit. Yes, applications such as carbon capture’s commercial viability is still unproven. But limiting action to proven technology would halt progress. ADN's projects have the potential to deliver real value to society. They deserve a chance to try to achieve their vision without being mocked with fake corporate accounts, and undermined with deliberate miss information.

Expand

If there were medals handed out for bagginess this post would win you the gold!

No.	Vol.	Price($)
9	851259	1.6¢

No.

Vol.

Price($)

851259

1.6¢

Price($)	Vol.	No.
1.7¢	2461117	4

Price($)

Vol.

No.

1.7¢

2461117

No.	Vol.	Price($)
7	819852	0.016
29	7958207	0.015
19	6833321	0.014
7	1955054	0.013
7	4499413	0.012

No.

Vol.

Price($)

819852

0.016

7958207

0.015

6833321

0.014

1955054

0.013

4499413

0.012

Price($)	Vol.	No.
0.017	2461117	4
0.018	2082665	7
0.019	1095711	7
0.020	2835030	15
0.021	1778214	12

Price($)

Vol.

No.

0.017

2461117

0.018

2082665

0.019

1095711

0.020

2835030

0.021

1778214

(20min delay)
Last 1.7¢		Change 0.001(6.25%)		Mkt cap ! $52.87M

Open	High	Low	Value	Volume
1.5¢	1.7¢	1.5¢	$106.1K	6.633M

General comments/chat, page-20121

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Revolutionary inverter technology leads the clean energy charge

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Emerald & Azure score Digger & Dealer awards

Bitcoin: Current State of Play & Where to Next | Swyftx

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

True North increases silver metal at QLD's Vero deposit by 20%

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

General comments/chat, page-20121

Top Stories

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Revolutionary inverter technology leads the clean energy charge

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Emerald & Azure score Digger & Dealer awards

Bitcoin: Current State of Play & Where to Next | Swyftx

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

True North increases silver metal at QLD's Vero deposit by 20%

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News